We read with interest the results of the phase 3 trial by Robert Croop and colleagues1 on the use of rimegepant for treatment of acute migraine. We feel that this study, like other similarly designed trials, has major problems in its methods, which suggests caution should be taken when examining the results.
Testing rimegepant for migraine-time to revise the trial design?
Torino, ClaudiaWriting – Review & Editing
;
2020
Abstract
We read with interest the results of the phase 3 trial by Robert Croop and colleagues1 on the use of rimegepant for treatment of acute migraine. We feel that this study, like other similarly designed trials, has major problems in its methods, which suggests caution should be taken when examining the results.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0140673620302415.pdf
accesso aperto
Descrizione: Testing rimegepant for migraine—time to revise the trial design?
Tipologia:
Versione Editoriale (PDF)
Licenza:
Altro tipo di licenza
Dimensione
44.24 kB
Formato
Adobe PDF
|
44.24 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
